CEOCFO Magazine Interviewed Aclipse Therapeutics CEO Raymond Houck

Aclipse Therapeutics Expands Drug Development Pipeline

Aclipse Therapeutics Expands Drug Development Pipeline with Signing of Exclusive, Worldwide License Agreement with Chong Kun Dang Pharmaceutical Corporation to

September 14, 2023

Aclipse Therapeutics receives a therapeutic development award of $1.475 million

Aclipse Therapeutics and its subsidiary Aclipse One Inc (“Aclipse” or “the Company”), an innovative biopharmaceutical company, today announced that the

April 20, 2022

Aclipse Therapeutics Announces $2.2 Million Grant from UK’s Medical Research Council for Development of M102

Funding Supports Aclipse Therapeutics’ and Sheffield Institute of Translational Neuroscience’s Development of M102 in Amyotrophic Lateral Sclerosis Radnor, PA —

February 8, 2021

Aclipse Therapeutics Awarded AUD 1 Million Grant from FightMND

Aclipse Therapeutics was awarded an AUD 1 million (approximately US $720,000) drug development research grant from FightMND, the largest independent

September 29, 2020

March 11, 2021

CEOCFO Magazine has interviewed Aclipse Therapeutics CEO Raymond Houck. Mr. Houck has introduced the background of the company and our lead drug product M102. He has also described the target pathomechanisms of M102 and its precision medicine approach to ALS and CNS diseases.

Learn More